MedTrace Logo

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

NCT01361009 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2017

Last updated 2014-05-16

Study results available
· View outcomes & findings →

Summary

This is an open-label, multicenter, non-interventional, prospective observational study. we collect the safety information of pramipexole over 12w treatment. Parkinson disease patients with different severity who have already used pramipexole could be observed in this study. In the whole observation period, treatment decision was determined by physician and patient completely. The safety endpoint is AE(Adverse Event), SAE(Serious Adverse Event), patient withdraw, laboratory test.

Conditions

  • Parkinson Disease

Interventions

DRUG

pramipexole

as prescibed by the investigator

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01361009 on ClinicalTrials.gov